切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2022, Vol. 11 ›› Issue (02) : 139 -143. doi: 10.3877/cma.j.issn.2095-3232.2022.02.006

临床研究

磁共振小视野扩散加权成像在局部进展期胰腺癌疗效预测中的价值
张瑜1, 郑楷炼2, 李欲晓3,()   
  1. 1. 201203 上海中医药大学附属曙光医院放疗科
    2. 200438 上海,海军军医大学第一附属医院肝胆胰外科
    3. 200438 上海,海军军医大学第一附属医院放射科
  • 收稿日期:2021-11-30 出版日期:2022-04-10
  • 通信作者: 李欲晓
  • 基金资助:
    申康中心临床"五新"创新研发项目(SHDC2020CR3087B); 长海医院234学科攀峰计划(2019YPT004)

Value of rFOV-DWI in predicting clinical efficacy of locally advanced pancreatic cancer

Yu Zhang1, Kailian Zheng2, Yuxiao Li3,()   

  1. 1. Department of Radiotherapy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    2. Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai 200438, China
    3. Department of Radiology, the First Affiliated Hospital of Naval Medical University, Shanghai 200438, China
  • Received:2021-11-30 Published:2022-04-10
  • Corresponding author: Yuxiao Li
引用本文:

张瑜, 郑楷炼, 李欲晓. 磁共振小视野扩散加权成像在局部进展期胰腺癌疗效预测中的价值[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 139-143.

Yu Zhang, Kailian Zheng, Yuxiao Li. Value of rFOV-DWI in predicting clinical efficacy of locally advanced pancreatic cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(02): 139-143.

目的

探讨磁共振小视野扩散加权成像(rFOV-DWI)在局部进展期胰腺癌临床疗效预测中的价值。

方法

本前瞻性研究对象为2015年1月至2017年7月在海军军医大学第一附属医院诊治的41例局部进展期胰腺癌患者。患者均签署知情同意书,符合医学伦理学规定。其中男28例,女13例;年龄44~80岁,中位年龄为64岁。41例均接受放疗,32例口服化疗药替吉奥。治疗前1周内接受3.0T MRI检查,检测病灶信号强度。生存分析采用Kaplan-Meier法和Log-rank检验。采用Cox比例风险回归模型筛选预后影响因素。采用预测误差曲线分析预测效能,评价指标为综合Brier评分(IBS)和C-index。

结果

局部进展期胰腺癌典型层面在3.0T rFOV-DWI图像表现为T1WI上呈稍低信号,T2WI上呈稍高信号,动脉期呈低强化,rFOV-DWI上呈高信号。感兴趣区域的信号强度中位数为537(357~943)。患者中位总体生存期、无瘤生存期分别为11.7、7.2个月。生存分析显示,胰体尾部癌无进展生存明显优于胰头部癌(χ2=5.165,P<0.05)。Cox多因素回归分析显示,信号强度及口服化疗药替吉奥均为患者总体生存的独立保护因素(HR=0.995,0.161;P<0.05);两者联合对总体生存预测的效能最高,IBS为0.152,C-index为0.673。

结论

局部进展期胰腺癌患者磁共振rFOV-DWI信号强度越强,口服化疗药替吉奥对患者总体生存越有益。

Objective

To evaluate the effect of reduced field-of-view diffusion-weighted imaging (rFOV-DWI) in predicting the clinical efficacy of locally advanced pancreatic cancer.

Methods

41 patients with locally advanced pancreatic cancer treated in the First Affiliated Hospital of Naval Medical University from January 2015 to July 2017 were enrolled in this prospective study. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 28 patients were male and 13 female, aged from 44 to 80 with a median age of 64 years. All 41 patients received radiotherapy, and 32 cases were treated with orally chemotherapeutic drug S-1. 3.0T MRI was performed within 1 week before treatment to detect the signal intensity of lesions. Survival analysis was conducted by Kaplan-Meier method and Log-rank test. Prognostic factors were screened by Cox proportional hazards regression model. The prediction efficiency was analyzed using prediction error curve. The evaluation indexes included integrated Brier score (IBS) and C-index.

Results

In 3.0T rFOV-DWI, typical planes of the locally advanced pancreatic cancer were manifested with slightly low signal intensity on T1WI, slightly high signal intensity on T2WI, low enhancement in the arterial stage and high signal intensity on rFOV-DWI. The median signal intensity of the region of interest was 537(357-943). The median overall survival and disease-free survival were 11.7 and 7.2 months, respectively. Survival analysis demonstrated that the progression-free survival of patients with pancreatic tail cancer was significantly better than that of their counterparts with pancreatic head cancer (χ2=5.165, P<0.05). Cox regression model showed that signal intensity and oral intake of S-1 were the independent protective factors for the overall survival of patients (HR=0.995, 0.161; P<0.05). The combination of these two yielded the highest efficiency in predicting the overall survival, with an IBS of 0.152 and C-index of 0.673.

Conclusions

The stronger the signal intensity of rFOV-DWI in patients with locally advanced pancreatic cancer, the better the overall survival of patients treated with oral intake of S-1.

图1 一例胰尾部局部进展期胰腺癌患者MRI图像注:a为T1WI上呈稍低信号,b为T2WI上呈稍高信号,c为动脉期呈低强化,d为rFOV-DWI上呈高信号(绿色框内为ROI),e为ADC图,f为常规DWI图像上呈高信号;rFOV-DWI为小视野扩散加权成像,DWI为扩散加权成像,ADC为表观扩散系数,ROI为感兴趣区域
图2 不同部位的局部进展期胰腺癌患者Kaplan-Meier生存曲线
表1 局部进展期胰腺癌患者OS影响因素Cox多因素回归分析
表2 局部进展期胰腺癌患者PFS影响因素Cox多因素回归分析
图3 小视野扩散加强成像SI值联合化疗药替吉奥对局部进展期胰腺癌患者的预测误差曲线注:IBS为综合Brier评分,SI为信号强度
[1]
Zhang Y, Zhu X, Liu R, et al. Combination of pre-treatment DWI-signal intensity and S-1 treatment: a predictor of survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy and sequential S-1[J]. Transl Oncol, 2018, 11(2):399-405.
[2]
李晶,马超,边云, 等. 小视野高分辨DWI对胰腺实性病变的鉴别诊断价值[J]. 中华胰腺病杂志, 2017, 17(6):394-399.
[3]
Ma C, Li YJ, Pan CS, et al. High resolution diffusion weighted magnetic resonance imaging of the pancreas using reduced field of view single-shot echo-planar imaging at 3 T[J]. Magn Reson Imaging, 2014, 32(2):125-131.
[4]
Kim H, Lee JM, Yoon JH, et al. Reduced field-of-view diffusion-weighted magnetic resonance imaging of the pancreas: comparison with conventional single-shot echo-planar imaging[J]. Korean J Radiol, 2015, 16(6):1216-1225.
[5]
Mannelli L, Monti S, Corrias G, et al. Comparison of navigator triggering reduced field of view and large field of view diffusion weighted imaging of the pancreas[J]. J Comput Assist Tomogr, 2019, 43(1):143-148.
[6]
张瑜,陈炜,王湘莲, 等. ADCtot值对射波刀联合替吉奥治疗局部进展期胰腺癌患者总生存期的预测价值[J]. 中华胰腺病杂志, 2018, 18(6):375-379.
[7]
Trajkovic-Arsic M, Heid I, Steiger K, et al. Apparent diffusion coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma[J]. Sci Rep, 2017, 7(1):17038.
[8]
Park MJ, Kim YK, Choi SY, et al. Preoperative detection of small pancreatic carcinoma: value of adding diffusion-weighted imaging to conventional MR imaging for improving confidence level[J]. Radiology, 2014, 273(2):433-443.
[9]
姚秀忠,曾蒙苏,饶圣祥, 等. 3.0T MR灌注加权成像和扩散加权成像在胰腺肿块诊断中应用[J]. 中华放射学杂志, 2011, 45(7):646-652.
[10]
Schoennagel BP, Habermann CR, Roesch M, et al. Diffusion-weighted imaging of the healthy pancreas: apparent diffusion coefficient values of the normal head, body, and tail calculated from different sets of b-values[J]. J Magn Reson Imaging, 2011, 34(4):861-865.
[11]
Klauss M, Lemke A, Grünberg K, et al. Intravoxel incoherent motion MRI for the differentiation between mass forming chronic pancreatitis and pancreatic carcinoma[J]. Invest Radiol, 2011, 46(1):57-63.
[12]
Niwa T, Ueno M, Ohkawa S, et al. Advanced pancreatic cancer. the use of the apparent diffusion coefficient to predict response to chemotherapy[J]. Br J Radiol, 2009, 82(973):28-34.
[13]
Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation[J]. Lancet, 2002, 360(9329):307-308.
[14]
Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients[J]. AJR Am J Roentgenol, 2007, 188(4):1001-1008.
[15]
Cui Y, Zhang XP, Sun YS, et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases[J]. Radiology, 2008, 248(3):894-900.
[16]
Ma C, Li J, Boukar MB, et al. Optimized ROI size on ADC measurements of normal pancreas, pancreatic cancer and mass-forming chronic pancreatitis[J]. Oncotarget, 2017, 8(58):99085-99092.
[17]
Ma C, Guo X, Liu L, et al . Effect of region of interest size on ADC measurements in pancreatic adenocarcinoma[J]. Cancer Imaging, 2017, 17(1):13.
[18]
Zhou X, Ma C, Wang Z, et al. Effect of region of interest on ADC and interobserver variability in thyroid nodules[J]. BMC Med Imaging, 2019, 19(1):55.
[19]
Cai PQ, Wu YP, An X, et al. Simple measurements on diffusion-wighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Eur Radiol, 2014, 24(11):2962-2970.
[20]
马超,刘莉,李晶, 等. 3.0T磁共振扩散加权成像信号强度对胰腺导管腺癌的诊断价值究[J]. 中华胰腺病杂志, 2015, 15(6):361-364.
[1] 丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志(电子版), 2023, 20(09): 930-938.
[2] 张莲莲, 惠品晶, 丁亚芳. 颈部血管超声在粥样硬化斑块易损性评估中的应用价值[J]. 中华医学超声杂志(电子版), 2023, 20(08): 816-821.
[3] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[4] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[5] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[6] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[7] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[8] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[9] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[10] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[11] 鲁鑫, 许佳怡, 刘洋, 杨琴, 鞠雯雯, 徐缨龙. 早期LC术与PTCD续贯LC术治疗急性胆囊炎对患者肝功能及预后的影响比较[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 648-650.
[12] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[13] 赵文毅, 邹冰子, 蔡冠晖, 刘永志, 温红. 超声应变力弹性成像联合MRI-DWI靶向引导穿刺在前列腺病变诊断中的应用[J]. 中华临床医师杂志(电子版), 2023, 17(9): 988-994.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要